{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=sample+analysis&page=66",
    "query": {
      "intervention": "sample analysis",
      "page": 66
    },
    "page_size": 10
  },
  "pagination": {
    "page": 66,
    "page_size": 10,
    "total_count": 1733,
    "total_pages": 174,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=sample+analysis&page=67&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=sample+analysis&page=65&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-16T05:52:16.019Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07805044",
      "title": "Truway Whole-Body Digital Twin and Physiologic Resilience Study (TRU-OMNIBODY)",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "PHYSIOLOGICAL PHENOMENA",
        "Homeostasis",
        "Physical Functional Performance",
        "Cardiorespiratory Fitness",
        "Cardiometabolic Risk Factors",
        "Mobility Limitation"
      ],
      "interventions": [
        {
          "name": "Standardized Physiologic Resilience Challenge",
          "type": "PROCEDURE"
        },
        {
          "name": "Multimodal Whole-Body Physiologic Monitoring",
          "type": "OTHER"
        },
        {
          "name": "Research-Only Whole-Body Digital Twin Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Truway Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 450,
      "start_date": "2026-08-31",
      "completion_date": "2041-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-11-16T05:52:16.019Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07805044"
    },
    {
      "nct_id": "NCT03698019",
      "title": "A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acral Lentiginous Melanoma",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Mucosal Melanoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 313,
      "start_date": "2019-02-15",
      "completion_date": "2026-10-30",
      "has_results": true,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-16T05:52:16.019Z",
      "location_count": 815,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 511 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03698019"
    },
    {
      "nct_id": "NCT02140021",
      "title": "Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cervical Adenocarcinoma",
        "Cervical Adenocarcinoma In Situ",
        "Cervical Intraepithelial Neoplasia",
        "Cervical Squamous Cell Carcinoma, Not Otherwise Specified",
        "Cervical Squamous Intraepithelial Neoplasia",
        "Early Invasive Cervical Adenocarcinoma",
        "Early Invasive Cervical Squamous Cell Carcinoma",
        "High Grade Cervical Squamous Intraepithelial Neoplasia",
        "High Grade Vaginal Intraepithelial Neoplasia",
        "Low Grade Vaginal Intraepithelial Neoplasia",
        "Stage I Cervical Cancer AJCC v8",
        "Stage I Vaginal Cancer AJCC v8",
        "Stage I Vulvar Cancer AJCC v8",
        "Stage IA Cervical Cancer AJCC v8",
        "Stage IA Vaginal Cancer AJCC v8",
        "Stage IA Vulvar Cancer AJCC v8",
        "Stage IA1 Cervical Cancer AJCC v8",
        "Stage IA2 Cervical Cancer AJCC v8",
        "Stage IB Cervical Cancer AJCC v8",
        "Stage IB Vaginal Cancer AJCC v8",
        "Stage IB Vulvar Cancer AJCC v8",
        "Stage IB1 Cervical Cancer AJCC v8",
        "Stage IB2 Cervical Cancer AJCC v8",
        "Stage II Cervical Cancer AJCC v8",
        "Stage II Vaginal Cancer AJCC v8",
        "Stage II Vulvar Cancer AJCC v8",
        "Stage IIA Cervical Cancer AJCC v8",
        "Stage IIA Vaginal Cancer AJCC v8",
        "Stage IIA1 Cervical Cancer AJCC v8",
        "Stage IIA2 Cervical Cancer AJCC v8",
        "Stage IIB Cervical Cancer AJCC v8",
        "Stage IIB Vaginal Cancer AJCC v8",
        "Stage III Cervical Cancer AJCC v8",
        "Stage III Vaginal Cancer AJCC v8",
        "Stage III Vulvar Cancer AJCC v8",
        "Stage IIIA Cervical Cancer AJCC v8",
        "Stage IIIA Vulvar Cancer AJCC v8",
        "Stage IIIB Cervical Cancer AJCC v8",
        "Stage IIIB Vulvar Cancer AJCC v8",
        "Stage IIIC Vulvar Cancer AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Vaginal Cancer AJCC v8",
        "Stage IV Vulvar Cancer AJCC v8",
        "Stage IVA Cervical Cancer AJCC v8",
        "Stage IVA Vaginal Cancer AJCC v8",
        "Stage IVA Vulvar Cancer AJCC v8",
        "Stage IVB Cervical Cancer AJCC v8",
        "Stage IVB Vaginal Cancer AJCC v8",
        "Stage IVB Vulvar Cancer AJCC v8",
        "Vaginal Adenocarcinoma",
        "Vulvar Adenocarcinoma",
        "Vulvar High Grade Squamous Intraepithelial Lesion",
        "Vulvar Intraepithelial Neoplasia",
        "Vulvar Squamous Cell Carcinoma",
        "Vulvar Squamous Intraepithelial Lesion"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 409,
      "start_date": "2014-10-27",
      "completion_date": "2025-07-08",
      "has_results": false,
      "last_update_posted_date": "2025-07-14",
      "last_synced_at": "2026-11-16T05:52:16.019Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02140021"
    },
    {
      "nct_id": "NCT05673200",
      "title": "Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Unresectable Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Decitabine and Cedazuridine",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2023-09-25",
      "completion_date": "2027-02-23",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-11-16T05:52:16.019Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Costa Mesa, California • Orange, California + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05673200"
    },
    {
      "nct_id": "NCT06351371",
      "title": "Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Erdafitinib",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2018-07-03",
      "completion_date": "2027-01-15",
      "has_results": true,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-11-16T05:52:16.019Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06351371"
    },
    {
      "nct_id": "NCT04089501",
      "title": "The Role of the Pregnane X Receptor (PXR) in Indole Signaling and Intestinal Permeability in Inflammatory Bowel Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Inflammatory Bowel Diseases"
      ],
      "interventions": [
        {
          "name": "Stool collection",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Biopsy collection",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 43,
      "start_date": "2015-02-25",
      "completion_date": "2019-05-02",
      "has_results": false,
      "last_update_posted_date": "2019-09-16",
      "last_synced_at": "2026-11-16T05:52:16.019Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04089501"
    },
    {
      "nct_id": "NCT00683371",
      "title": "Microarray Analysis of Sinus Samples From Patients With and Without Chronic Rhinosinusitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Maxillary Sinusitis"
      ],
      "interventions": [
        {
          "name": "Specimen collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2007-10",
      "completion_date": "2008-04-30",
      "has_results": false,
      "last_update_posted_date": "2020-02-05",
      "last_synced_at": "2026-11-16T05:52:16.019Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00683371"
    },
    {
      "nct_id": "NCT01772771",
      "title": "Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glioma",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Malignant Solid Neoplasm",
        "Melanoma",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Genetic Testing",
          "type": "OTHER"
        },
        {
          "name": "Medical Chart Review",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 12000,
      "start_date": "2012-03-01",
      "completion_date": "2033-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-11-16T05:52:16.019Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01772771"
    },
    {
      "nct_id": "NCT07925268",
      "title": "Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Prostate Cancer (NEPC)",
        "Metastatic Prostate Adenocarcinoma",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Ifinatamab Deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography (PET)/Computerized Tomography (CT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Computerized Tomography (CT)/ Magnetic Resonance Imaging (MRI)",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood Specimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Rahul Aggarwal",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2026-11-07",
      "completion_date": "2031-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-09",
      "last_synced_at": "2026-11-16T05:52:16.019Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07925268"
    },
    {
      "nct_id": "NCT05773274",
      "title": "Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Digestive System Neuroendocrine Tumor G1",
        "Metastatic Digestive System Neuroendocrine Tumor G2",
        "Unresectable Digestive System Neuroendocrine Tumor G1",
        "Unresectable Digestive System Neuroendocrine Tumor G2"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Lutetium Lu 177 Dotatate",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2024-01-12",
      "completion_date": "2029-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-16T05:52:16.019Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05773274"
    }
  ]
}